Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model

Kenji Nishikawa, Eiji Okanari, Yuuko Shinohara, Hironobu Matsunaga, Hiroshi Nishida, Noriaki Iwase, Shigeru Ushiyama
European Respiratory Journal 2016 48: PA4032; DOI: 10.1183/13993003.congress-2016.PA4032
Kenji Nishikawa
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiji Okanari
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuuko Shinohara
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hironobu Matsunaga
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Nishida
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriaki Iwase
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeru Ushiyama
1Pharmaceuticals Research Laboratory, Ube Industries, Ltd., Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Lysophosphatidic acid (LPA) is known as a fibrotic lipid mediator. Mice lacking LPA1 receptor or treated with a LPA1 antagonist are protected from bleomycin (BLM)-induced pulmonary fibrosis. However, the therapeutic efficacy has not yet been reported. Therefore we evaluated therapeutic effect of LPA antagonism and a role of LPA in the later fibrotic phase of BLM model using a novel LPA1 antagonist, UD-009.

Methods: Potency and selectivity of UD-009 were assessed with recombinant LPA receptors and in normal human lung fibroblasts. In a BLM model, animals were administered with BLM i.v. for 5 days from day 0, and treated with UD-009 (30 mg/kg, p.o., b.i.d.) either from day 0 to 28 for prophylactic assay or from day 14 to 28 for therapeutic assay. The differentiation of fibroblasts was assessed by using primary cultured fibroblasts isolated from the lungs of BLM-injured mice by staining with anti-α-SMA antibody.

Results: UD-009 is a potent and selective LPA1 antagonist. Prophylactic treatment of UD-009 significantly reduced collagen accumulation in the BLM model. Interestingly, UD-009 showed inhibition predominantly in the later phase of the model. Primary cultured fibroblasts isolated from the lungs of the BLM-injured mice receiving UD-009 decreased the expression of α-SMA compared to the control. Moreover, therapeutic treatment of UD-009 caused almost same effects as those of the prophylactic treatment.

Conclusions: UD-009 is a newly identified LPA1 antagonist and shows clear therapeutic efficacy by restraining the fibrotic phase when the fibroblasts are activated and differentiated. LPA may therefore control progression of fibrotic disorders in IPF.

  • Interstitial lung disease
  • Animal models
  • Pharmacology
  • Copyright ©the authors 2016
Previous
Back to top
Vol 48 Issue suppl 60 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model
Kenji Nishikawa, Eiji Okanari, Yuuko Shinohara, Hironobu Matsunaga, Hiroshi Nishida, Noriaki Iwase, Shigeru Ushiyama
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4032; DOI: 10.1183/13993003.congress-2016.PA4032

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model
Kenji Nishikawa, Eiji Okanari, Yuuko Shinohara, Hironobu Matsunaga, Hiroshi Nishida, Noriaki Iwase, Shigeru Ushiyama
European Respiratory Journal Sep 2016, 48 (suppl 60) PA4032; DOI: 10.1183/13993003.congress-2016.PA4032
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Prostacyclin and VEGF in the rejection process after lung transplantation – A possible biomarker
  • Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice
  • Refinement of the hyperoxia-based experimental mouse model of bronchopulmonary dysplasia
Show more 3.3 Mechanisms of Lung Injury and Repair

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society